Fosun Pharma Subsidiary Wins Approval for Sodium Nitroprusside Injection

Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an update.

Shanghai Fosun Pharmaceutical announced that its subsidiary Yaopharma Co., Ltd. has received approval from the National Medical Products Administration for the drug registration of Sodium Nitroprusside Injection. The product is indicated for hypertensive emergencies, including hypertensive crises and perioperative blood pressure control, as well as acute heart failure such as acute pulmonary edema and heart failure associated with acute myocardial infarction or valve insufficiency, expanding the subsidiary’s cardiovascular treatment portfolio and strengthening the group’s position in critical-care therapeutics.

The approval of Sodium Nitroprusside Injection enriches Fosun Pharma’s hospital-use injectable offerings, particularly in the cardiovascular and acute care segment. This development is expected to support the company’s competitiveness in China’s high-demand market for emergency cardiovascular drugs and may enhance its relationships with medical institutions that rely on stable supplies of essential critical-care medications.

The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based healthcare group engaged in the research, development, manufacturing and distribution of pharmaceutical products. The company operates across prescription drugs, medical devices and related services, with a focus on both domestic and overseas markets through its network of subsidiaries.

Average Trading Volume: 2,598,987

Technical Sentiment Signal: Sell

Current Market Cap: HK$72.19B

For an in-depth examination of 2196 stock, go to TipRanks’ Overview page.